BRAF and thyroid gland carcinoma: The BRAF V600E or other mutations (e.g., TERT promoter mutation or RET/PTC fusions and so on) could demonstrate mutations typical of classic PTC.[29] In this study, 59 high-frequency mutations and targeted drug-related genes (e.g., BRAF, TERT, PTEN, TP53, PIK3CA, RAS, RET and so on) that may be related to thyroid cancer was determined by NGS, but the genetic test results showed that only BRAF gene mutations (L597Q and V600E in 2 separate lesions) occurred in the patient.